A study into efficacy of omalizumab therapy in patients with severe persistent allergic asthma at a tertiary referral centre for asthma in Ireland

QJM: An International Journal of Medicine

Volumn 106, Issue 7, 2013, Pages 631-634

  Subramaniam, A ^a   Al Alawi, M ^a   Hamad, S ^a   O'Callaghan, J ^a   Lane, S J ^a  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; OMALIZUMAB; SALBUTAMOL;

ADULT; ALLERGIC ASTHMA; ARTICLE; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DRUG EFFICACY; FEMALE; HOSPITALIZATION; HUMAN; LUNG FUNCTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEVERE PERSISTENT ASTHMA; TREATMENT RESPONSE;

EID: 84880317168     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hct072     Document Type: Article

References (14)

1. Guidelines for the Diagnosis and Management of Asthma. Bethesda. http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (31 December 2012, date last accessed).
2. Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004; 59:701-8.
3. Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir J 1996; 9:636-42.
4. Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60:302-8.
5. Costello RW, Long DA, Gaine S, Mc Donnell T, Gilmartin JJ, Lane SJ. Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs. Ir J Med Sci 2011; 180:637-41.
6. Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol 2004; 114:265-9.
7. Van Hove CL, Moerloose K, Maes T, Joos GF, Tournoy KG. Cigarette smoke enhances Th-2 driven airway inflammation and delays inhalational tolerance. Respir Res 2008; 9:42.
8. Yang SR, Chida AS, Bauter MR, Shafiq N, Seweryniak K, Maggirwar SB, et al. Cigarette smoke induces proinflammatory cytokine release by activation of NF-kappaB and posttranslational modifications of histone deacetylase in macrophages. Am J Physiol Lung Cell Mol Physiol 2006; 291:L46-57.
9. Busse W, Corren J, Lanier BQ, Mcalary M, Fowler-Taylor A, Cioppa GD, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184-90.
10. Soler M, Matz J, Townley R, Buhl R, O'brien J, Fox H, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirements in allergic asthmatics. Eur Respir J 2001; 18:254-61.
11. Berger WE. Monoclonal anti-IgE antibody: a novel therapy for allergic airways disease. Ann Allergy Asthma Immunol 2002; 88:152-60.
12. Milgrom H, Fick RB Jr, Su JQ, Reimann JD, Bush RK, Watrous ML, et al. Treatment of allegic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med 1999; 341:1966-73.
13. Soler M, Matz J, Townley R, Buhl R, O'brien J, Fox H, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:254-61.
14. Nopp A, Johansson SG, Adedoyin J, Ankerst J, Palmqvist M, Oman H. After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy 2010; 65:56-60.